These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1011 related items for PubMed ID: 27438590

  • 1. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V, König A, Seufferlein T.
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [Abstract] [Full Text] [Related]

  • 2. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
    Le N, Vinci A, Schober M, Krug S, Javed MA, Kohlmann T, Sund M, Neesse A, Beyer G.
    Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
    [Abstract] [Full Text] [Related]

  • 3. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A, Pernot S, Siauve N, Landi B, Lepère C, Colussi O, Rougier P, Zaanan A, Verrière B, Taieb J.
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [Abstract] [Full Text] [Related]

  • 4. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG.
    JAMA Surg; 2020 Sep 01; 155(9):832-839. PubMed ID: 32667641
    [Abstract] [Full Text] [Related]

  • 5. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL, Tougeron D, Pernot S, Pozet A, Béchade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Williet N, Desrame J, Artru P, Soularue E, Le Roy B, Taieb J.
    Clin Res Hepatol Gastroenterol; 2020 Jun 01; 44(3):295-301. PubMed ID: 31607641
    [Abstract] [Full Text] [Related]

  • 6. Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
    Vogel A, Ciardiello F, Hubner RA, Blanc JF, Carrato A, Yang Y, Patel DA, Ektare V, de Jong FA, Gill S.
    Cancer Treat Rev; 2016 Nov 01; 50():142-147. PubMed ID: 27676174
    [Abstract] [Full Text] [Related]

  • 7. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ, Kim H, Shin K, Hong TH, Suh JH, Lee MA.
    BMC Cancer; 2021 Nov 03; 21(1):1176. PubMed ID: 34732161
    [Abstract] [Full Text] [Related]

  • 8. Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
    Surinach A, Phung T, Abdul-Rahim O, Khushman M.
    Curr Oncol; 2020 Apr 03; 27(2):e222-e225. PubMed ID: 32489272
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V, German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators.
    Lancet Gastroenterol Hepatol; 2021 Feb 03; 6(2):128-138. PubMed ID: 33338442
    [Abstract] [Full Text] [Related]

  • 11. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
    Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D'Andrea MR.
    World J Gastroenterol; 2017 Aug 28; 23(32):5875-5886. PubMed ID: 28932079
    [Abstract] [Full Text] [Related]

  • 12. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S, Siebenhüner AR, Winder T, Meisel A, Fritsch R, Astaras C, Szturz P, Borner M.
    Cancer Treat Rev; 2021 May 28; 96():102180. PubMed ID: 33812339
    [Abstract] [Full Text] [Related]

  • 13. Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
    Hann A, Bohle W, Egger J, Zoller WG.
    Z Gastroenterol; 2016 Oct 28; 54(10):1138-1142. PubMed ID: 27723905
    [Abstract] [Full Text] [Related]

  • 14. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ, Berger AW, Perkhofer L, Daum S, König A, Dickhut A, Wittel U, Wille K, Geissler M, Algül H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T.
    BMC Cancer; 2018 Dec 29; 18(1):1298. PubMed ID: 30594153
    [Abstract] [Full Text] [Related]

  • 15. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
    Mizusawa J, Fukutomi A, Katayama H, Ishii H, Ioka T, Okusaka T, Ueno H, Ueno M, Ikeda M, Mizuno N, Ozaka M, Fukuda H, Furuse J, Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group.
    Pancreatology; 2018 Oct 29; 18(7):841-845. PubMed ID: 30075908
    [Abstract] [Full Text] [Related]

  • 16. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
    McBride A, Bonafede M, Cai Q, Princic N, Tran O, Pelletier C, Parisi M, Patel M.
    Expert Rev Clin Pharmacol; 2017 Oct 29; 10(10):1153-1160. PubMed ID: 28795609
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
    Ghosn M, Ibrahim T, Assi T, El Rassy E, Kourie HR, Kattan J.
    World J Gastroenterol; 2016 Dec 14; 22(46):10124-10130. PubMed ID: 28028360
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C, Bitzer M, Malek NP, Plentz RR.
    Scand J Gastroenterol; 2014 Dec 14; 49(12):1480-5. PubMed ID: 25390691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.